BMS-986278 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to Globaldata, it is involved in 9 clinical trials, of which 7 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of BMS-986278’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BMS-986278 is expected to reach an annual total of $33 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BMS-986278 is under development for the treatment of pulmonary fibrosis including idiopathic pulmonary fibrosis (IPF) and progressive fibrotic interstitial lung diseases. The drug candidate is administered orally. It acts by targeting lysophosphatidic acid 1 (LPA1) receptor.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,159 million for the fiscal year ended December 2022 (FY2022), a decrease of 0.5% over FY2021. In FY2022, the company’s operating margin was 20.9%, compared to an operating margin of 18.6% in FY2021. In FY2022, the company recorded a net margin of 13.7%, compared to a net margin of 15.1% in FY2021. The company reported revenues of US$11,337 million for the first quarter ended March 2023, a decrease of 0.6% over the previous quarter.
For a complete picture of BMS-986278’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.